Inventiva (NASDAQ:IVA) Now Covered by TD Cowen

TD Cowen initiated coverage on shares of Inventiva (NASDAQ:IVA) in a report issued on Friday, MarketBeat.com reports. The brokerage issued a buy rating and a $10.00 price objective on the stock.

Several other equities analysts have also recently issued reports on the company. UBS Group started coverage on Inventiva in a research report on Tuesday, November 12th. They issued a “neutral” rating and a $3.00 price objective on the stock. Stifel Nicolaus decreased their target price on shares of Inventiva from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, November 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $13.00 target price on shares of Inventiva in a report on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $12.60.

Inventiva Stock Up 3.6 %

IVA opened at $2.84 on Friday. The business has a 50 day simple moving average of $2.33 and a two-hundred day simple moving average of $2.36. Inventiva has a one year low of $1.53 and a one year high of $4.50.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.